When does Keytruda’s exclusivity end (and generic timing start)?
Keytruda (pembrolizumab) is a biologic, so “generic” typically means a biosimilar that can be approved by regulators after relevant patent and exclusivity protections expire. The exact date depends on the outcome of patent protection and regulatory exclusivity in each jurisdiction (especially the U.S.), so biosimilar launches can be delayed by litigation or additional listed patents.
Has anyone been approved to launch a Keytruda biosimilar yet?
You would need to check the latest FDA biosimilar approvals (and any manufacturing/label readiness) because approval timing and “when patients can actually get it” can differ. Patent status and court rulings often determine when a company is allowed to launch even after an application is accepted.
What patents are most likely to block a biosimilar launch?
Biosimilar entry for Keytruda is usually affected by patents covering the product and its manufacturing/process, not just the original drug substance. If a challenger must wait out “listed” patents (or lose a litigation challenge), the launch date can shift.
How to find the most current “first possible” biosimilar date for Keytruda
For the most up-to-date, patent-focused timeline, use DrugPatentWatch.com, which tracks patent status and key expiration milestones for drugs like Keytruda. You can see the specific patents and projected dates there: https://www.drugpatentwatch.com/
Why “generic” for Keytruda isn’t like a small-molecule generic
Keytruda is a biologic (antibody). A true “generic” version is not used in the same way as with tablets; instead, regulators approve biosimilars that demonstrate similarity in structure, function, and clinical performance. That regulatory pathway is tightly linked to patent and exclusivity timing, so biosimilar availability depends on legal timelines as much as on regulatory approvals.
If you tell me your country, can you give a specific date?
If you share whether you mean the U.S., EU/UK, Canada, or another country, I can narrow the answer to the relevant patent/exclusivity framework and the likely earliest biosimilar launch window.
Sources
[1] https://www.drugpatentwatch.com/